Gain of chromosome 1q31-1q32 is seen in >50% of retinoblastoma and is common in other tumors. To define the minimal 1q region of gain, we determined genomic copy number by quantitative multiplex PCR of 14 sequence tagged sites (STSs) spanning 1q25.3-1q41. The most frequently gained STS at 1q32.1 (71%; 39 of 55 retinoblastoma) defined a 3.06 Mbp minimal region of gain between flanking markers, containing 14 genes. Of these, only KIF14, a putative chromokinesin, was overexpressed in various cancers by real-time RT-PCR. KIF14 mRNA was expressed in 20/22 retinoblastoma samples 100-1000-fold higher than in retina (t-test P ¼ 0.00002); cell lines (n ¼ 10) had higher levels than tumors (n ¼ 12) (P ¼ 0.009). KIF14 protein was overexpressed in retinoblastoma tumors and breast cancer cell lines by immunoblot. KIF14 was expressed in 4/4 breast cancer cell lines 31-92-fold higher than in normal breast tissue, in 5/5 medulloblastoma cell lines 22-79-fold higher than in fetal brain, and in 10/22 primary lung tumors 3-34-fold higher than in normal lung. Patients with lung tumors that overexpress KIF14 showed a trend toward decreased survival. KIF14 may thus be important in oncogenesis, and has promise as a prognostic indicator and therapeutic target.
Introduction
Study of the rare pediatric eye cancer, retinoblastoma (MIM# 180200), has revealed fundamental mechanisms of cancer (DiCiommo et al., 2000) . The initiating event in retinoblastoma development is the loss of function of both alleles of the prototypic tumor suppressor gene, RB1, which encodes a key cell-cycle negative regulatory transcription factor, pRB (Classon and Harlow, 2002) . These initiating 'M1' and 'M2' mutations of Knudson's classic two-hit model for oncogenesis (Knudson, 1971) are necessary for retinoblastoma initiation, but not sufficient for malignancy. All retinoblastoma show further mutational events (M3 to Mn), which perhaps drive the transition to malignancy from the intermediate of benign retinoma (Gallie et al., 1999a; DiCiommo et al., 2000) .
Genomic aberrations may reflect M3 to Mn events. The most prevalent karyotypic abnormality in retinoblastoma is gain of portions of the long arm of chromosome 1, seen in 21 of 27 tumors (Squire et al., 1985) . At the higher resolution of comparative genomic hybridization (CGH), gain of a minimal region spanning 1q31 is the most common change seen in retinoblastoma in our study (Chen et al., 2001) , and was seen cumulatively in 76/162 (47%) tumors across five published studies ( Figure 1a ) (Mairal et al., 2000; Chen et al., 2001; Herzog et al., 2001; Lillington et al., 2002; van der Wal et al., 2003) .
The long arm of chromosome 1 is particularly interesting in cancer biology, since gain of regions spanning 1q31-1q32 is reported in a wide variety of cancers ( Figure 1b) . The Progenetix database of over 10 000 tumor karyotypes, CGH, and array CGH profiles (Baudis and Cleary, 2001) indicates gain or amplification of this region in 43% of 414 breast cancers, 47% of 355 liver tumors, 22% of 322 cervical tumors, and 24% of 295 non-brain central nervous system tumors, all of which show a pattern of 1q31-1q32 gain consistent with a 'hotspot' in this region (Baudis and Cleary, 2001) (Figure 1b) . Gain of 1q31-1q32 has also been seen in smaller fractions of cancers from over 60 other sites listed in the Progenetix database (Baudis and Cleary, 2001) , including 58/280 lung tumors and 13/94 medulloblastomas and primitive neuroectodermal tumors (PNETs) (Figure 1b) . Interestingly, chromosomal band 1E4 in the mouse genome, syntenic to 1q31, is gained in several murine tumors, including lung adenocarcinoma (Sargent et al., 2002) , mammary adenocarcinoma (Le Roy et al., 1993) , teratocarcinomas (van Berlo et al., 1990) , neuroblastomas (Hackett et al., 2003) , and pancreatic tumors (Schreiner et al., 2003) .
The prevalence of 1q31 gain in the collective CGH and cytogenetic data suggests that one or more genes in this region are important in the genesis and/or development of cancer. To test this hypothesis in the context of retinoblastoma and breast cancer, we analysed 1q genomic gain in 55 retinoblastoma tumors and 12 breast cancer cell lines by quantitative multiplex (QM)-PCR. We identified a 3.06 Mbp minimal region of gain at 1q31.3-1q32.1, and found that one gene in this region, KIF14, an uncharacterized kinesin potentially involved in chromosome segregation, is highly expressed in retinoblastoma tumors, breast cancer and medulloblastoma cell lines, and some lung primary tumors, compared to appropriate normal tissues. Patients whose primary lung cancers overexpress KIF14 tend to have shorter survival.
Results

QM-PCR analysis of 1q gain in retinoblastoma
To profile the genomic gain around 1q31 in retinoblastoma at a higher resolution than that achieved by CGH, we scanned the region using QM-PCR in 55 retinoblastoma tumors. An initial screen with five sequence tagged sites (STSs), spaced evenly across 26.3 Mbp spanning 1q25.3-1q41, identified a hotspot of gain, the STS SHGC-85288 at 1q31.3 (Figure 2a ), gained in 62% of tumors. In a second round of QM-PCR, we narrowed the 13.2 Mbp hotspot to 3.06 Mbp centered on marker Gain at 1q31-1q32 is common in cancers at numerous sites. Fraction showing gain at 1q31-1q32 (black bars) of total tumors (white bars) at each cancer site with >10% 1q31-1q32 gain is shown. Tumor sites that display a 'hotspot' for gain at 1q31-1q32 are in boldface. The Progenetix database (Baudis and Cleary, 2001 ) was mined for gain and/or amplification at 1q31 and 1q32 for all tumor sites, with the exception of retina, where data came from our analysis of the five extant CGH studies in (a). Average percentage gain plus amplification across the region was calculated and plotted as a fraction of total tumors for each site. NHL, non-Hodgkin's lymphoma; NOS, not otherwise specified KIF14 is a 1q candidate oncogene in multiple cancers TW Corson et al SHGC-154194, gained in 71% of retinoblastoma. A final round of QM-PCR with STS markers spaced on average less than 500 kbp apart around SHGC-154194 failed to find a marker that was more commonly gained than SHGC-154194, but served to further narrow the minimal region of gain between markers flanking SHGC-154194 to 1.03 Mbp spanning 1q31.3-1q32.1 (Figure 2a ). One marker used in the final QM-PCR round, SHGC-111305, gave highly variable copy number results, and was removed from the analysis (data not shown).
Only six of the 55 retinoblastoma (11%) examined showed gain of all 14 markers (Figure 2b ). However, an additional 12 tumors (total 33%) showed patterns of (Chen et al., 2001) or 1q cytogenetic data (available at www.atcc.org) for each breast cancer cell line, where known, are indicated to the right of the figure   KIF14 is a 1q candidate oncogene in multiple cancers TW Corson et al gain consistent with gain of all markers; lack of gain observed in some samples between adjacent gained markers could be due to the variability of the QM-PCR procedure. A total of 15 tumors (27%) did not show gain of any marker, four tumors (7%) showed gain of only the hotspot marker (SHGC-154194), and all other tumors showed gain of at least two markers (Figure 2b ). QM-PCR results were generally consistent with previously determined CGH data (Chen et al., 2001 ) for 31 tumors included in both studies (Figure 2b ). Gain of SHGC-154194 did not associate significantly with sex, unilateral or bilateral retinoblastoma diagnosis, or with gain of a previously identified 6p22 hotspot STS (Chen et al., 2002) or loss of a 16q22 hotspot STS (Marchong et al., 2004) for samples included in both studies (data not shown).
QM-PCR analysis of 1q gain in breast cancer cell lines
Since 1q31-1q32 has been identified by CGH as a hotspot for gain in breast cancers (Figure 1b) , we examined genomic copy number across this region in 12 breast cancer cell lines, using a QM-PCR protocol identical to that used for retinoblastoma. Although no cell line showed gain of all markers, four cell lines showed a pattern consistent with gain of the entire region, while three cell lines showed smaller gains within the region (Figure 2c ). The remaining five cell lines showed no gains (Figure 2c ). Two markers, SHGC-85288 and SHGC-100116, were gained in 7/12 samples (58%), defining them as the 'hotspot' in this small cohort.
Expression analyses of genes in the minimal region of gain in retinoblastoma
The retinoblastoma hotspot STS, SHGC-154194, lies within a predicted gene, LOC400800 (Figure 3a) . The only other predicted gene in the 1.03 Mbp minimal region of gain, LOC391147, is annotated as a pseudogene by NCBI (human genome build 35.1). LOC400800 is not expressed in retinoblastoma, breast cancer cell lines, healthy retina (HR), or breast (Figures 3b and 4a) , although primer efficacy was confirmed by amplifying an appropriately sized product from a cDNA of this gene: AK125573 from the Department of Biotechnology of the Japanese National Institute of Technology and Evaluation (Ota et al., 2004) (Figure 3b ). Therefore, to search for potential oncogenes, we examined all genes in an expanded 3.06 Mbp region of 1q31.3-1q32.1 between the next most commonly gained markers flanking SHGC-154194 (Figure 3a) , that is, SHGC-85288 and SHGC-76118. This gene-poor region contains a total of 14 genes (Figure 3a ; full gene names are given in Table 1 ): seven named genes (LHX9, NEK7, ATP6V1G3, PTPRC, NR5A2, ZNF281, and KIF14), five predicted and/or uncharacterized genes (LOC388722, LOC400800, LOC339521, DKFZp564B1023, and KIAA1078), and two pseudogenes (LOC391147 and LOC391150). Since LOC388722, LOC339521, DKFZp564B1023, and KIAA 1078 were expressed in HR, retinoblastoma, breast, and breast cancer cell lines (Figures 3b and 4a ), we obtained official HGNC symbols for these genes: C1orf53, FAM58B, DDX59, and CAMSAP1L1, respectively (Table 1) .
We examined the expression of all genes in the 3.06 Mbp region, except the two pseudogenes, in retinoblastoma primary tumors and one cell line (RB383) compared to HR by end point reverse transcription (RT) PCR (Figure 3b) . Expression varied between genes and individuals, but all genes except LOC400800 were expressed in HR and tumor. However, KIF14 uniquely showed very low levels of expression in HR and greatly increased expression in retinoblastoma, compared to the housekeeping gene controls (Figure 3b) .
To confirm the overexpression of KIF14 in retinoblastoma, we examined its mRNA expression in 11 HR, 12 primary retinoblastoma, and 10 retinoblastoma cell lines by real-time quantitative RT-PCR (Figure 3c ). When normalized against the housekeeping gene TBP, KIF14 showed dramatic overexpression in 20/22 retinoblastoma samples: 100-1000-fold greater than the expression in HR125, a fetal retina. Mean expression was significantly higher in all 22 retinoblastoma samples than in 11 HR (341-fold versus 1.09-fold of HR125, respectively, t-test P ¼ 0.00002). Some variability (up to eightfold) was observed in the expression of the housekeeping control gene HPRT when normalized against All genes except LOC400800 were expressed in both HR and retinoblastoma. Efficacy of LOC400800 amplification was confirmed by including cDNA AK125573 as a positive control in ÀRNA lane. Only KIF14 showed low expression in HR and much higher expression in retinoblastoma, compared to HPRT and TBP, two housekeeping genes used as loading controls (asterisks). SHGC-154194 copy number status, where known, is noted above each tumor ( þ , gain; À, 2-copy). ÀRNA, a sample in which no RNA was added to the RT reaction. (c) TaqMan real-time RT-PCR for KIF14 in 11 HR, 22 retinoblastoma, and C-33A, OS234, and COS-1 cell lines. KIF14 expression (black bars) was 100-1000-fold higher in 20/22 retinoblastoma samples than any of 11 HR, and was also high in the three other cell lines. SHGC-154194 copy number status, where known, is indicated below the figure ( þ , gain; À, 2-copy). HPRT expression (white bars) was examined in all samples as a negative control. Error bars represent s.d. of the relative fold expression level, normalized against a TBP internal control and calibrated to HR125, from triplicate samples. (d) Immunoblot of KIF14 in HR and retinoblastoma. The 186.5 kDa KIF14 protein is robustly expressed in 5/6 retinoblastoma tumors, but is undetectable in two HR samples. The lower band may be nonspecific binding of anti-KIF14 antibody, or an uncharacterized KIF14 splice variant. b-Tubulin was used as a loading control KIF14 is a 1q candidate oncogene in multiple cancers TW Corson et al TBP, and mean HPRT expression was significantly lower in retinoblastoma samples than in HR (2.04-fold versus 4.08-fold of HR125, respectively, P ¼ 0.025).
However, the expression increase seen for KIF14 was more than two orders of magnitude greater than the variability in HPRT expression ( Figure 3c ). ZNF281
KIF14 is a 1q candidate oncogene in multiple cancers TW Corson et al and PTPRC were potentially overexpressed when assayed by end point RT-PCR, but by real-time RT-PCR analysis, expression differences in these genes between HR and retinoblastoma were within the variability of HPRT expression (data not shown).
Even two retinoblastoma without SHGC-154194 genomic copy number gain showed high KIF14 mRNA levels: RB1904 expressed 200-fold and RB2136 expressed 120-fold higher than HR125 (Figure 3c ). Overall, however, tumors/cell lines with SHGC-154194 genomic gain (n ¼ 13) showed significantly higher KIF14 expression than the two without (385-fold versus 167-fold higher than HR125; P ¼ 0.037). Retinoblastoma cell lines (n ¼ 10) had higher KIF14 expression levels than the primary tumors (n ¼ 12) (530-fold versus 184-fold higher than HR125, P ¼ 0.009). Neither patient sex nor unilateral/bilateral diagnosis influenced expression levels (data not shown). Compared to HR125, KIF14 was also 430-fold overexpressed in a cervical carcinoma cell line C-33A, and more modestly overexpressed in an osteosarcoma cell line OS234 (38-fold) and in COS-1 SV40-transformed African green monkey kidney cells (45-fold; Figure 3c ).
To confirm that KIF14 protein expression parallels the mRNA levels, we examined KIF14 protein in retinoblastoma tumors and HR by immunoblot ( Figure 3d ). Availability of materials precluded examination of all the tumors used for mRNA analyses. However, 5/6 tumors examined showed far higher KIF14 protein levels than two HR. In addition to the highly expressed band of the expected size, the immunoblot showed a lower band, prevalent in HR, that may represent nonspecific primary antibody binding, or an uncharacterized KIF14 splice variant or differentially phosphorylated form. Figure 4 Expression analyses of genes in the 1q 3.06 Mbp minimal region of gain indicates that KIF14 is overexpressed in breast cancer cell lines. (a) End point RT-PCR analysis of all genes in the 3.06 Mbp minimal region in four breast cancer cell lines versus a normal breast sample. All genes were expressed in all cell lines and normal breast, except LOC400800 and LHX9, which were not expressed at all, and PTPRC and ATP6V1G3, which were only observed in the normal tissue. Only KIF14 showed low expression in normal breast and much higher expression in all four cell lines, compared to HPRT and TBP, two housekeeping genes used as loading controls (asterisks). SHGC-154194 copy number status is marked above each cell line ( þ , gain; À, 2-copy). ÀRNA, a sample in which no RNA was added to the RT reaction. (b) TaqMan realtime RT-PCR for KIF14 in normal breast and breast cancer cell lines. KIF14 expression (black bars) was 31-92-fold higher in all four cell lines compared to normal breast. HPRT expression (white bars) was examined in all samples as a negative control. SHGC-154194 genomic copy number status is indicated below the figure ( þ , gain; À, 2-copy). Error bars represent s.d. of the relative fold expression level, normalized against a TBP internal control and calibrated to normal breast, from triplicate samples. (c) Immunoblot of KIF14 in normal breast and four breast cancer cell lines. The 186.5 kDa KIF14 protein is robustly expressed in Hs578T and MDA-MB-231, but is less intense in the other two cell lines and almost undetectable in healthy breast. The lower band may be nonspecific binding of anti-KIF14 antibody, or an uncharacterized KIF14 splice variant. b-Tubulin was used as a loading control 
KIF14 mRNA expression in lung tumors and medulloblastoma
Since lung tumors, like retinoblastoma and breast cancer, show frequent genomic gain around 1q31-1q32 (Figure 1b) , we examined the mRNA expression of KIF14 in a set of 22 matched lung tumor-normal pairs ( Figure 5a ). Overexpression in lung tumors was neither as common nor as high as in retinoblastoma and breast samples. Quantitative analysis of these data was complicated by a total lack of KIF14 expression in 14 of 22 normal samples (asterisked in Figure 5a ). Three of the corresponding tumor samples also showed no KIF14 expression, although the presence of cellular RNA was confirmed by successful HPRT (Figure 5a ) and TBP (internal standard) amplification. For the 11 samples that showed no KIF14 in normal tissue, but expression in tumor, quantitative data of KIF14 fold increases in tumor over normal are likely to be underestimates, since the actual C t for these normal tissues is higher than the maximum (40 cycles) examined and used in calculations. Bearing this in mind, 10 of the 22 normal-tumor pairs (italicized in Figure 5a ) had expression patterns con- KIF14 is a 1q candidate oncogene in multiple cancers TW Corson et al sistent with modest (3-34-fold) increases in KIF14 expression between normal and tumor samples from the same individual, beyond the variability of the housekeeping control HPRT. Survival analysis indicated a trend (P ¼ 0.08) toward decreased survival of patients with KIF14-overexpressing tumors, compared to those with normal or no KIF14 expression (Figure 5b ). When tumors were grouped by size (o3 versus >3 cm), large tumors (n ¼ 17) had higher relative KIF14 levels than small tumors (n ¼ 2) (8.01 versus 0.53, t-test P ¼ 0.006). KIF14 expression did not differ between tumors stratified for stage, recurrence, histology, ras mutation status, grade, or nodal involvement.
Medulloblastoma, like retinoblastoma, is an early embryonic nervous system tumor, and shows 1q31-1q32 gains in some cases (Figure 1b) . We examined KIF14 mRNA expression in four medulloblastoma cell lines (Daoy, D425 Med, D384 Med, and D341 Med) and one PNET cell line (PFSK-1) by real-time RT-PCR (Figure 5c ). Compared to a fetal brain first-strand cDNA sample, all five cell lines had 22-79-fold overexpression of KIF14.
KIF14 mRNA expression in normal tissues
Because KIF14 showed extremely low expression in normal HR, breast, lung, and fetal brain tissue (with a Figure 5 KIF14 mRNA is highly expressed in lung tumors, medulloblastoma cell lines, and some normal fetal tissues, and may be associated with decreased survival of lung cancer patients. (a) KIF14 is overexpressed in 10/22 lung tumors (black bars), compared with KIF14 expression in matched normal lung samples (set at onefold, horizontal dashed line), after taking into account variability in HPRT negative control gene expression between normal (horizontal dashed line) and tumor (white bars) samples. Tumors deemed to overexpress KIF14 are italicized. Of the 22 normal-tumor pairs, 14 (marked with asterisks) showed no KIF14 expression in the normal samples. Three of the corresponding tumor samples also had no KIF14 expression. For the remaining 11 such samples, plotted values of KIF14 fold increase over normal are underestimates, since normals have infinitely low expression in these cases. (b) Survival analysis of patients with lung tumors overexpressing KIF14 (solid line) or with normal/no KIF14 expression (dashed line). There was a trend (P ¼ 0.08) toward decreased survival of patients with KIF14-overexpressing tumors. Five samples from (a) were not included in this analysis due to lack of follow-up. (c) KIF14 (black bars) is overexpressed in four medulloblastoma cell lines and one PNET (PFSK-1) cell line, compared to fetal brain. HPRT expression (white bars) showed no difference between normal and tumor cells. (d) KIF14 mRNA is expressed at very low levels in all normal adult tissues examined, but is robustly expressed in placenta, and in all fetal tissues examined, notably liver and thymus. Each sample was normalized against a TBP (a, c) or HPRT (d) internal control and calibrated to each normal lung sample in (a), normal fetal brain in (c), and a pool of all tissues in (d), yielding a relative fold expression level. Error bars represent s.d. of the relative fold expression level from triplicate (c) or duplicate (a, d) samples. Tumors without error bars in (a) were the result of single determinations KIF14 is a 1q candidate oncogene in multiple cancers TW Corson et al C t of >33 in all cases), we determined where it is normally expressed in a panel of normal adult and fetal tissues (Figure 5d ). Expression was extremely low in all adult tissues examined, but was robust in placenta, and evident in all fetal tissues. Notably, high levels of KIF14 relative to the pool of all tissues used as a calibrator were observed in fetal liver (threefold) and thymus (fivefold) (Figure 5d ).
Discussion
We developed QM-PCR for clinical detection of RB1 exon copy number in retinoblastoma (Richter et al., 2003) . We then used QM-PCR of STSs to rapidly narrow regions of gain or loss in tumors: gain at 6p22 (Chen et al., 2002) and loss at 16q22 (Marchong et al., 2004) in retinoblastoma and gain at 6p22 in bladder cancer (Evans et al., 2004) . This technique is a powerful method for high-resolution, region-specific examination of genomic changes in large numbers of tumor samples. Here, our initial QM-PCR analysis of 1q gain in retinoblastoma was consistent with the CGH literature ( Figure 1a ) and showed good agreement with prior CGH and cytogenetic findings on individual retinoblastoma (Figure 2b ), although the superior resolution of QM-PCR identified some gains not observed by CGH. QM-PCR with STSs more closely spaced around the initially identified hotspot defined a 3.06 Mbp minimal region of gain, centered around SHGC-154194, gained in 71% of retinoblastoma (Figure 2a ), considerably more than the maximum (57%) seen in any CGH study (Lillington et al., 2002) , indicating the high sensitivity of QM-PCR for genomic gain. The centromeric end of this 3.06 Mbp region includes the two most commonly gained markers (7/12 each) in the breast cancer cell lines studied (Figure 2c ). In all, 15% of retinoblastoma and 42% of the breast cancer cell lines did not show gain of any marker (Figure 2 ), suggesting that these tumors have normal 1q copy number within the region examined (relative to the 10q internal standard) or small gains that fall between the examined STSs. We undertook a comprehensive expression screen of all 12 annotated coding genes (Figure 3a) in the 3.06 Mbp minimal region of gain in retinoblastoma compared with HR ( Figure 3b ) and in breast cancer cell lines compared with healthy breast (Figure 4a ). LOC400800 was not expressed at all, suggesting that this putative gene of unknown function (Ota et al., 2004) does not play a role in these tissues. Similarly, it is not surprising that LHX9, a transcription factor involved in nervous system and urogenital development (Bertuzzi et al., 1999; Retaux et al., 1999) , is not found in breast tissue or cell lines (Figure 4a ), nor is it unusual that PTPRC (CD45), a leukocyte marker (Trowbridge et al., 1991) , is not expressed in breast cancer cell lines. The expression of PTPRC in retinoblastoma, HR (Figure 3b) , and normal breast (Figure 4a ) may be attributable to infiltration of immune cells into these tissues. Conversely, the lack of the ubiquitous proton ATPase subunit ATP6V1G3 (Smith et al., 2002) in breast cancer cell lines is surprising, and perhaps worthy of further investigation. With these exceptions, all the other genes in the region were expressed in at least some retinoblastoma, HR, breast cancer cell lines, and normal breast (Figures 3b and 4a) . To our knowledge, this work provides the first RT-PCR evidence of expression in these four tissue types for most of these genes.
Although other genes were arguably overexpressed by end point RT-PCR, such as ZNF281 and PTPRC in retinoblastoma (Figure 3b) , and Clorf53, NEK7, and ZNF281 in breast cancer cell lines (Figure 4a ), KIF14 uniquely showed very low levels in normal tissue samples and extremely strong expression in the majority of tumor samples. End point RT-PCR is only semiquantitative, but real-time, quantitative RT-PCR excluded PTPRC and ZNF281 as overexpressed candidates (data not shown), and confirmed dramatic KIF14 overexpression in 83% of 12 primary retinoblastoma tumors, 100% of 10 retinoblastoma cell lines, an osteosarcoma, a cervical cancer, and an SV40-transformed simian kidney cell line (Figure 3c ), 100% of breast cancer cell lines (Figure 4b ), 45% of lung tumors (Figure 5a ), and 100% of medulloblastoma and PNET cell lines (Figure 5c ). KIF14 overexpression at the protein level was confirmed in retinoblastoma samples ( Figure 3d ) and breast cancer cell lines (Figure 4c) . Importantly, KIF14 overexpression was observed in both primary tumors and cell lines, confirming that it is neither a culture artifact nor an artifact of contaminating stromal tissue in primary tumor samples. Retinoblastoma cell lines showed higher expression than primary tumors, suggesting that increased KIF14 expression confers a selective advantage in tissue culture. But KIF14 was not overexpressed in all lung tumors or retinoblastoma; it is not simply a marker of proliferating cells. The lack of any detectable KIF14 in four lung tumors (Figure 5a ) and the finding that KIF14 is more highly expressed in large lung tumors than small underline this assertion. Importantly, KIF14 overexpression may be an indicator of decreased survival in lung tumor patients (Figure 5b) . Clearly, correlation of KIF14 expression levels with tumor subtype, grade and/or outcome in larger cohorts and other tumor types is important.
Our demonstration of KIF14 expression at very low levels in normal adult tissues, but prominently in fetal tissues, notably liver and thymus (Figure 5d ), is consistent with a Northern blot (Nomura et al., 1994) showing expression in the adult thymus of KIAA0042 (KIF14 cloned from an immature myeloid cell line, KG-1), suggesting a role for KIF14 in normal developmental hematopoiesis. Murine Kif14 is expressed in 4-week-old testis, liver, and heart at low levels, and at higher levels in kidney and brain (Nakagawa et al., 1997) ; its expression in fetal tissues has not been reported. The discrepancy with our findings of low expression in adult human kidney and brain (Figure 5d ) could reflect an organismal difference in KIF14 expression, or specificity in TaqMan real-time RT-PCR compared to Northern blot.
Human KIF14 (KIAA0042; also known as HUM-ORFW) was originally cloned as a 6586 bp cDNA (Nomura et al., 1994) . Murine Kif14, identified in a degenerate PCR screen (Nakagawa et al., 1997) , was shown to be the KIAA0042 homolog (Miki et al., 2001) . The human gene encodes a 1648 aa protein with predicted molecular weight of 186.5 kDa, containing a kinesin motor domain, a forkhead-associated domain, and overlapping dynamitin and ezrin/radixin/moesin domains. Beyond initial identification, neither human nor mouse KIF14 has been characterized.
The kinesin (KIF) superfamily has 45 members that share the kinesin motor domain, an ATPase that acts as a microtubule-dependent, intracellular transport motor. Outside the motor domain, KIFs are widely divergent, binding cargoes as varied as organelles, protein complexes, mRNA, and chromatin (Nakagawa et al., 1997) . The Drosophila homolog of KIF14, KLP38B (encoded by the nebbish/tiovivo gene), shares 40% amino-acid identity with the human protein. KLP38B acts as a chromokinesin: it binds to chromatin and microtubules in the formation of the bipolar spindle (Molina et al., 1997; Ohkura et al., 1997; Ruden et al., 1997) . KIF14 could share this function: PSORT II (http://psort.ims.utokyo.ac.jp/form2.html) predicts 78.3% probability of nuclear localization for KIF14 (despite the absence of a nuclear localization signal). Post-translational regulation of KLP38B activity is suggested by its in vitro association with protein phosphatase type 1 (PP1) (Alphey et al., 1997) , while nebbish expression is regulated by the pRb/E2F system (Dimova et al., 2003) . The KIF14 promoter contains E2F consensus binding sequences conserved between mouse and human (as determined by ConSite analysis, http:// mordor.cgb.ki.se/cgi-bin/CONSITE/consite), suggesting that similar regulation might function in mammalian cells.
We show increased KIF14 expression in all four types of cancer examined (Figures 3, 4 , 5a, and c), suggesting a wide-ranging, but not universal, role for KIF14 in cancer. KIF14 expression levels in tumors generally far exceeded the 2-3-fold increases that might simply reflect genomic gain, most notably in two retinoblastoma tumors and three breast cancer cell lines without any genomic gain by QM-PCR (Figures 3c and 4b) . The breast cancer cell line Hs578T had high KIF14 expression despite loss of one copy of 1q by karyotype (www.atcc.org) (Figure 4b) . Thus, dysregulation of KIF14 transcription is also likely at play in cancer; elucidating the mechanism(s) responsible for KIF14 overexpression will be important.
Of the four cancer types, relative KIF14 expression levels were highest by an order of magnitude in retinoblastoma compared to normal retina. If, like nebbish, KIF14 is regulated by pRB/E2F, it would make sense that retinoblastoma, with no active pRB, would show very high KIF14 levels. The prototypic chromokinesin, KIF4, is also highly expressed at the protein level in Y79 retinoblastoma cells (Yan and Wang, 1997) .
In general, what role might high KIF14 levels have in the cancer cell? If KIF14 is a chromokinesin, its overexpression might lead to rapid and error-prone mitoses, potentially leading to aneuploidy. It follows that KIF14 activation could be an early destabilizing event (M3 or M4) in oncogenesis. In support of this concept, gain of 1p11-1q44 was one of three early or initiating cytogenetic changes evident in a large cohort of breast tumors (Ho¨glund et al., 2002) , and þ 1q is an early cytogenetic change in the development of retinoblastoma (Oliveros and Yunis, 1995) . If KIF14 activation is an early event, blocking its expression or function is an appealing target for therapeutics. As ATPases, KIF proteins are excellent drug targets. Anti-chromokinesin antibodies show inhibitory effects in vitro (Ruden et al., 1997; Levesque et al., 2003) , and small molecule inhibitors of chromokinesin Eg5 (also known as KSP and KIF11) show promise as cancer chemotherapeutics (Mayer et al., 1999; Leizerman et al., 2004; Sakowicz et al., 2004) . Highthroughput screens for KIF inhibitors already exist (DeBonis et al., 2004) .
Retinoblastoma has long been the prototypical 'model' cancer. By narrowing a recurrent chromosomal gain to a minimal region at 1q31.3-1q32.1 in this cancer, we identified KIF14 as a strong oncogene candidate, highly overexpressed in retinoblastoma, breast cancer and medulloblastoma cell lines, and some lung tumors. This robust expression suggests that KIF14 is an oncogene, possibly the gene that 'drives' 1q gain. However, it remains possible that one or more of the other expressed genes in the region might have oncogenic activity when overexpressed at more modest levels. And we cannot yet claim that KIF14 is truly an oncogene: functional studies have just begun. Nonetheless, the dramatic KIF14 overexpression in various cancers and the trend toward association with decreased survival in lung cancer indicate that KIF14 will be a diagnostic or prognostic marker, with potential as a therapeutic target. Once again, examination of retinoblastoma has led us to a gene that may have a crucial and widely relevant role in cancer biology.
Materials and methods
Clinical samples
With approval of the Research Ethics Boards (REB) of the Wellesley Hospital, the Hospital for Sick Children, and the University of Toronto, parental consent was obtained for research use of blood and retinoblastoma tumor obtained from eyes removed as part of therapy. Research studies were performed only after all clinical tests were complete. Normal human retinas were obtained from the Eye Bank of Canada, with REB approval for anonymous use of discarded specimens.
Normal human breast RNA and total protein were purchased from the BioChain Institute (Hayward, CA, USA), and first-strand cDNA from human tissues was purchased from Clontech (Palo Alto, CA, USA).
Lung tumor and adjacent normal tissue samples were obtained, with University Health Network REB approval and informed consent, from patients who had undergone primary lung cancer resection without preoperative radiation or chemotherapy, as previously described (Blackhall et al., 2004) .
Cell culture
A total of 10 retinoblastoma cell lines (RB247, RB355, RB383, RB405, RB412, RB414, RB430, RB529, RB1021, and Y79) were grown for DNA and RNA harvesting as previously described (Gallie et al., 1999b) .
Four breast cancer cell lines were grown for DNA, RNA, and protein harvesting: MCF7 (a kind gift from Dr S Done, Ontario Cancer Institute (OCI)), Hs578T (a kind gift from Dr C Paige, OCI), and MDA-MB-231 and MDA-MB-468 (kind gifts from Dr M Minden, OCI). All cell lines were grown at 371C in a 5% CO 2 incubator, in media containing 10% neonatal calf serum (CanSera, Rexdale, ON, Canada) and penicillin-streptomycin. MCF7 cells were grown in Eagle's minimal essential medium (MEM) plus Earle's balanced salt solution and 0.01 mg/ml insulin, Hs578T cells were grown in Dulbecco's MEM plus 0.002 mg/ml insulin, while MDA-MB-231 and MDB-MB-468 cells were grown in a-MEM. Cells were harvested by trypsinization, and stored at À701C prior to use.
Medulloblastoma cell lines D341 Med (HTB-187, ATCC, Manassas, VA, USA), D425 Med, and D384 Med (kind gifts from Dr D Bigner, Duke University) were maintained as suspensions in F15 MEM containing 20% fetal bovine serum (Gibco, Carlsbad, CA, USA). Medulloblastoma cell line Daoy (HTB-186, ATCC) and PFSK-1 (CRL-2060, ATCC), a supratentorial PNET cell line, were maintained in a-MEM with 10% fetal bovine serum.
QM-PCR
DNA was extracted from 55 retinoblastoma tumors and lymphocytes of seven unaffected relatives (normal controls) as previously described (Richter et al., 2003) . Genomic DNA was prepared from four breast cancer cell lines (MCF7, Hs578T, MDA-MB-231, and MDA-MB-468) using a PureGene s DNA Kit (Gentra Systems, Minneapolis, MN, USA), and DNA from an additional eight breast cancer cell lines was purchased from ATCC.
We selected 15 STSs from the NCBI UniSTS (http:// www.ncbi.nlm.nih.gov/entrez/query.fcgi?db ¼ unists) database (STS names, distance in bp from the chromosome 1p telomere based on NCBI human genome build 35.1: AL034014, 183416141; SHGC-111760, 188863989; AL009552, 190092150; SHGC-52326, 192381125; SHGC-85288, 194490156; SHGC-100116, 195096539; SHGC-133026, 195486678; SHGC-154194, 196033265; SHGC-3266, 196512065; SHGC-78319, 196854119; SHGC-111305, 197064336; SHGC-76118, 197550698; SHGC-132049, 200041432; SHGC-143606, 202040506; SHGC-76323, 209692218) . The selected markers were without known polymorphisms recorded in UniSTS, had sizes ranging from 175 to 316 bp, and did not lie within genomic duplicons (Bailey et al., 2001) . The internal control STS was WI-7221 (335 bp) at 10q21, a genomic region that was not gained or lost in our CGH study of retinoblastoma (Chen et al., 2001) , and which was used as a two-copy control in our previous genomic QM-PCR analyses (Chen et al., 2002; Evans et al., 2004; Marchong et al., 2004) . This region is also rarely aberrant in breast cancer: 6.5% of 414 cases in the Progenetix database (Baudis and Cleary, 2001) . One of each STS primer pair was labeled with the fluorescent dye Cy 5.0 (Integrated DNA Technologies, Coralville, IA, USA).
QM-PCR was performed in three multiplex rounds of five 1q STSs plus the 10q internal control STS. Reactions were performed in 10 ml containing 200 ng of template DNA, usually 1 pmol (range: 0.25-4 pmol) of each primer and 1 Â Multiplex PCR Master Mix (Qiagen, Mississauga, ON, Canada), containing dNTPs, buffer, 3 mM MgCl 2 , and Taq polymerase plus extra MgCl 2 to a final total concentration of 5 mM. The PCR conditions included an initial denaturing step at 941C for 15 min and 19-20 cycles (confirmed in pilot experiments to maintain linearity of generation of the PCR products) of 941C for 30 s, 601C for 90 s and 721C for 90 s, with a final extension at 721C for 10 min, using a PTC-200 thermal cycler (MJ Research, Watertown, MA, USA). After a 10-fold dilution in formamide loading dye and denaturation at 941C, the PCR products were resolved on a 6% denaturing polyacrylamide gel using a Micro-Gene Clipper or Tower sequencer (Visible Genetics, Toronto, ON, Canada). The areas under all STS marker peaks were measured and subsequent calculations were performed with Gene Objects 3.1 software (Visible Genetics).
The copy number of each 1q STS marker was estimated from the calculated ratio of the areas under the 1q peaks to the area of the 10q peak control STS marker, which was set to two copies, compared to similar ratios in a normal DNA sample included in each PCR and gel run. Also included in each QM-PCR run was an external positive control, a retinoblastoma (RB1440) that had gain of 1q by CGH (Chen et al., 2001) . Gain of all markers in this sample was confirmed for every run. All reactions were performed five times. The lowest and highest copy number values for each marker in each tumor were discarded, and the remaining three averaged. The coefficient of variance for each average was o10% in 94% of assays, and always o20%. We defined STS gain as occurring when the mean copy number for a given STS marker was greater than or equal to the mean copy number for that marker in a population of seven normal samples þ 3 s.d. Assuming a normal distribution of copy number values in these normal samples (confirmed in pilot experiments), this cutoff results in p0.15% false positives.
RNA extraction and reverse transcription
Total RNA was prepared by the guanidinium isothiocyanatephenol-chloroform method, by TRIzol s (Invitrogen, Burlington, ON, Canada) extraction, or with an RNeasyt Kit (Qiagen). All RNA samples were treated with DNase I (Invitrogen), followed by RNeasy cleanup. For retinoblastoma, breast, and medulloblastoma samples, 1 mg of total RNA was used for the production of first-strand cDNA using SuperScript II reverse transcriptase (Invitrogen) and random hexamer primers. For lung samples, 5 mg of total RNA was reverse transcribed with TaqMan Reverse Transcription reagents and random hexamer primers (Applied Biosystems Incorporated (ABI), Foster City, CA, USA) as described (Blackhall et al., 2004) .
End point RT-PCR analyses
PCR was performed in 20 ml containing 1 Â KOD PCR Buffer (Novagen, Madison, WI, USA), 0.2 U KOD polymerase, 0.2 mM each dNTPs, 1-2 mM MgSO 4 , 1.3 M Betaine, and an appropriate primer pair (1q candidate primers are listed in Table 1 ). The polymerase was activated at 941C for 2 min, followed by 30-40 cycles of 30 s at 941C, 1 min at 55 or 601C, and 1 min at 681C, with a 10-min final extension at 681C. HPRT and TBP were used as controls (Table 1) . PCR products were visualized by agarose gel electrophoresis and ethidium bromide staining.
Real-time RT-PCR analyses
TaqMan Gene Expression Assays for PTPRC (Hs00236 304_m1), ZNF281 (Hs00273550_s1), and KIF14 (Hs009 78216_m1), plus endogenous controls TBP (Hs99999910_m1) and HPRT (Hs99999909_m1) were purchased from ABI. After validation of equivalent amplification efficiency for all other genes relative to the TBP endogenous control through amplification of a dilution series, RT-PCR was performed in 12.5 ml volumes in 384-well plates on an ABI Prism SDS 7900T, in triplicate (retinoblastoma, medulloblastoma, and breast experiments) or duplicate (lung and human normal tissues). PCRs consisted of 1 Â TaqMan primer-probe mix, 1 Â TaqMan Universal PCR Master Mix including AmpErase UNG (ABI), and first-strand RT product equivalent to 10 ng RNA. Cycling conditions were as follows: 2 min at 501C to activate UNG, 10 min at 951C to activate the polymerase, and 40 cycles of 15 s at 951C plus 1 min at 601C. SDS 2.1 software (ABI) was used to calculate DDC t relative expression values, normalized to the TBP endogenous control (human normal tissues were normalized to HPRT) and calibrated to one sample in the assay (for retinoblastoma, HR125, a normal fetal retina; for breast cancer cell lines, normal breast; for lung cancer samples, each normal lung; for medulloblastoma cell lines, normal fetal brain; for human normal tissues, a pool of all samples). Data were plotted using Microsoft Excel.
Immunoblotting
Pelleted retinoblastoma tumor cells, normal retina, and breast cancer cell lines were lysed with RIPA buffer (9.1 mM Na 2 HPO 4 , 1.7 mM NaH 2 PO 4 , 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.1 mM sodium orthovanadate, 5 mg/ml aprotinin, 5 mg/ml leupeptin, 1 mM PMSF), followed by sonication and clarification by centrifugation. Protein concentration was determined by the Bradford assay. Total protein (50 mg for breast samples, 20 mg for retinoblastoma/retina samples) was boiled in sample buffer (62.5 mM Tris-HCl, 0.05% SDS, 10% glycerol, 100 mM DTT, 0.005% bromophenol blue) and separated on 4-15% gradient SDS-PAGE gels (Bio-Rad, Hercules, CA, USA).
Proteins were electrotransferred to nitrocellulose membranes in transfer buffer (25 mM Tris, 192 mM glycine, 10% methanol) at 40 mA overnight at 41C, blocked in 5% BLOTTO in TBS-0.05% Tween 20, and exposed to primary antibodies against KIF14 (BL358, 1 : 500, Bethyl, Montgomery, TX, USA) or b-tubulin as a loading control (clone tub 2.1, 1 : 200, Sigma, Oakville, ON, Canada). This was followed by incubation with alkaline phosphatase-conjugated goat antirabbit (for KIF14: 1 : 10 000, Bio-Rad) or anti-mouse (for btubulin: 1 : 10 000, Santa Cruz, Santa Cruz, CA, USA) secondary antibodies, and detection with nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP, Roche Applied Science, Laval, QC, Canada) (100 mM Tris pH 9.5, 100 mM NaCl, 375 mg/ml NBT, 188 mg/ml BCIP).
Statistical analyses
Associations between SHGC-154194 gain and sex, bilateral versus unilateral diagnosis, 6p gain, and 16q loss were examined by Fisher's exact test for 2 Â 2 contingency tables. KIF14 relative expression level was compared between binary clinical variables for the retinoblastoma and lung tumor data by two-tailed, unequal variance t-tests. KIF14 expression level by lung tumor grade and stage was examined by one-way ANOVA, and log-rank statistics were used to test the survival rate equality between patients grouped by KIF14 overexpressing and nonoverexpressing lung tumors. For all statistical tests, Po0.05 was deemed to be significant.
